Loading organizations...
Lipogems International develops and commercializes medical technologies focused on regenerative medicine. Its core offering is the Lipogems® system, a proprietary device designed to process a patient's own adipose tissue into a micro-fragmented product. This technology harnesses the inherent reparative capabilities of fat tissue to support the natural healing and restoration of damaged tissues.
The company was established in 2010 as an Italian biotech firm, rooted in the insight that autologous adipose tissue holds significant potential for tissue repair and regeneration. This approach aims to provide a safe and effective solution by utilizing the body's own resources, which has driven the development of their processing system.
Physicians in various disciplines, including orthopaedics, general surgery, and wound healing, utilize the Lipogems system to address conditions ranging from degenerative osteoarticular pathologies to traumatic injuries. Lipogems' long-term vision is to enhance patient quality of life by continuously advancing innovative medical devices for tissue processing and making these responsible and effective solutions accessible worldwide.
Lipogems International has raised $15.0M across 2 funding rounds.
Lipogems International has raised $15.0M in total across 2 funding rounds.
Lipogems International has raised $15.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2022 | $13M Series A | — | LIFTT | Announced |
| Jul 1, 2022 | $2M Seed | — | LIFTT | Announced |
Lipogems International has raised $15.0M in total across 2 funding rounds.
Lipogems International's investors include LIFTT.
Lipogems International is an Italian biotech multinational company headquartered in Milan, with a U.S. presence in Norcross, Georgia, specializing in regenerative medicine through its proprietary Lipogems® system. This FDA-cleared medical device harvests, processes, and deploys a patient's own adipose (fat) tissue—known as microfat—via a minimally invasive, enzyme-free method to support tissue repair and healing, serving orthopedic surgeons, general surgeons, and plastic surgeons treating conditions like knee osteoarthritis, joint damage, and wounds.[1][2][3][4] It addresses the problem of limited non-surgical options for patients unsuitable for invasive procedures, enabling faster recovery and lifestyle restoration; over 60,000 procedures have been performed globally across 29 countries, backed by 140+ independent peer-reviewed publications, including 5-year follow-up data in orthopedics.[5][6]
The company targets patients exhausted by conservative therapies, offering a compliant, point-of-care alternative used in 250+ U.S. orthopedic centers and military sites, with strong growth evidenced by a €12.5M ($13.2M) funding round in 2022 to fuel FDA IDE studies for knee osteoarthritis.[2][5][6]
Founded as a privately held medical device company in Italy, Lipogems International Spa emerged to pioneer adipose-derived regenerative solutions, drawing on historical uses of fat tissue for healing—dating back to World War I wound treatment—and modern research into its stem cell potential.[1][4] The core Lipogems® system achieved U.S. 510(k) clearance in 2014 as the first device for harvesting, concentrating, and transferring autologous adipose tissue under FDA minimal manipulation guidelines for homologous use.[2][3][4]
Key milestones include global distribution starting in 27 (now 29) countries, accumulation of 125+ (now 140+) peer-reviewed studies by 2022, and expansion via 2022 growth capital from LIFTT SpA—a healthcare VC firm led by serial entrepreneur Stefano Buono—to advance clinical trials.[5][6] Leadership figures like Giorgio Ninzoli (President, Lipogems International) and Carl Llewellyn (President, Lipogems USA) have driven its evolution from a reparative medicine innovator to a leader in orthopedics and beyond.[5]
Lipogems rides the explosive growth in regenerative medicine, particularly adipose-derived therapies, amid rising demand for biologics that leverage the body's healing potential over pharmaceuticals or implants—fueled by aging populations, osteoarthritis prevalence (affecting millions), and post-pandemic shifts toward minimally invasive outpatient care.[4][5][6] Timing aligns with stringent FDA regulations on human cellular/tissue products (HCT/Ps under 21 CFR 1271), where Lipogems' 2014 clearance positioned it as a compliant pioneer ahead of enforcement curves.[2][4]
Market forces like escalating orthopedic procedure costs, surgeon preferences for evidence-based biologics, and military validation favor its expansion; it influences the ecosystem by partnering with institutions for research, standardizing microfat as a mainstream tool, and enabling continuum-of-care models that keep patients out of major surgery.[1][5] This democratizes access to next-gen adipose tech, challenging traditional interventions in a $50B+ global regen med market.
Lipogems is primed for acceleration, with ongoing FDA IDE studies in knee OA poised to unlock disease-specific indications, potentially boosting U.S. adoption beyond general use and mirroring its global traction.[6] Trends like AI-driven personalization in regen med, expanded wound care applications, and payer reimbursement for biologics will shape its path, alongside further independent trials building on 140+ publications.
Its influence may evolve from niche innovator to category leader, influencing standards in orthobiologics and inspiring enzyme-free platforms; as funding and data compound, expect deeper integration into value-based care, tying back to its mission of harnessing "the power of fat" for natural, patient-centric healing.[1][5][7]
